Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes
The Open Diabetes Journal · 2009
DOI: 10.2174/1876524600902010060 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Diabetes Journal, 2009. Verfasst von Sachiko Honjo und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
We investigated the efficacy and safety of miglitol, a new alpha-glucosidase inhibitor, by switching from voglibose in Japanese patients with type 2 diabetes.Subjects included those who had previously been administered with voglibose (n=90, 0.6mg/day).After voglibose was changed into miglitol (150mg/day), HbA 1C level, body weight and abdominal symptoms were evaluated six months later.HbA 1C level was significantly decreased from 7.8±1.2 to 7.3±1.0%(P
Zitieren
APA
Honjo, S., Ikeda, H., Kawasaki, Y., Wada, Y., Hamamoto, Y., Aoyama, T., Kimura, T., Nomura, K., & Koshiyama, H. (2009). Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes. The Open Diabetes Journal. https://doi.org/10.2174/1876524600902010060
Vancouver
Honjo S, Ikeda H, Kawasaki Y, Wada Y, Hamamoto Y, Aoyama T, et al. Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes. The Open Diabetes Journal. 2009. doi:10.2174/1876524600902010060
BibTeX
@article{Honjo2009,
author = {Honjo, Sachiko and Ikeda, Hiroki and Kawasaki, Yukiko and Wada, Yoshiharu and Hamamoto, Yoshiyuki and Aoyama, Tomohisa and Kimura, Tetsuya and Nomura, Kazuhiro and Koshiyama, Hiroyuki},
title = {Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes},
journal = {The Open Diabetes Journal},
year = {2009},
doi = {10.2174/1876524600902010060}
}
EUVIMED